Cancer Data Science Laboratory, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Thoracic and GI Malignancies Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA.
Cell Rep Med. 2023 Feb 21;4(2):100938. doi: 10.1016/j.xcrm.2023.100938. Epub 2023 Feb 10.
Malignant mesothelioma is an aggressive cancer with limited treatment options and poor prognosis. A better understanding of mesothelioma genomics and transcriptomics could advance therapies. Here, we present a mesothelioma cohort of 122 patients along with their germline and tumor whole-exome and tumor RNA sequencing data as well as phenotypic and drug response information. We identify a 48-gene prognostic signature that is highly predictive of mesothelioma patient survival, including CCNB1, the expression of which is highly predictive of patient survival on its own. In addition, we analyze the transcriptomics data to study the tumor immune microenvironment and identify synthetic-lethality-based signatures predictive of response to therapy. This germline and somatic whole-exome sequencing as well as transcriptomics data from the same patient are a valuable resource to address important biological questions, including prognostic biomarkers and determinants of treatment response in mesothelioma.
恶性间皮瘤是一种侵袭性癌症，治疗选择有限，预后不良。更好地了解间皮瘤的基因组学和转录组学可以推进治疗方法。在这里，我们展示了一个包含 122 名患者的间皮瘤队列，以及他们的种系和肿瘤全外显子组和肿瘤 RNA 测序数据，以及表型和药物反应信息。我们确定了一个 48 个基因的预后标志，该标志对间皮瘤患者的生存具有高度预测性，其中包括 CCNB1，其表达本身就高度预测了患者的生存。此外，我们还分析了转录组学数据，以研究肿瘤免疫微环境，并确定基于合成致死性的可预测对治疗反应的特征。来自同一患者的种系和体细胞全外显子组测序以及转录组学数据是解决重要生物学问题的宝贵资源，包括间皮瘤的预后生物标志物和治疗反应的决定因素。
